




Figure 1: Chemical Structures of Illustrative Nucleosides




β -D-2'-CH₃-riboG




β -D-2'-CH₃-riboC




β -D-2'-CH₃-riboU




β -D-2'-CH₃-riboA




β -D-2'-CH₃-riboI




β -D-2'-CH₃-riboT




β -D-1'-CH₃-riboA



β -D-1'-CH₃-riboG




FIAU



Ribavirin

Figure 2: Screening Pharmacokinetics of β -D-2'-CH₃-riboG in Cynomolgus Monkeys



09863816-052301

Figure 3: Pharmacokinetics of β -D-2'-CH₃-riboG in Cynomolgus Monkeys






Figure 4: BVDV Cell Protection Assay (CPA) Of β -D-2'-CH₃-riboG



Cell Protection Assay






Figure 5: BVDV Cell Protection Assay (CPA) of Ribavirin



Cell Protection Assay




Figure 6: BVDV Cell Protection Assays




Figure 7: Plaque Purified BVDV




Figure 8: BVDV Plaque Assay of β-D-2'-CH₃-riboU





Figure 9: Yield Reduction Assay of β -D-2'-CH₃-riboG



4-log virus reduction at 9 μ M

Figure 10: BVDV Yield Reduction Assay for β -D-2'-CH₃-riboC

